Injection site reactions, unusual fatigue , dizziness , and gastrointestinal symptoms beyond what the drug typically causes could indicate contamination
In our recent article about GLP-1s, Angela Meadows, Louise Adams and I created tables for tirzepatide and semaglutide that show the topline results, adverse events, and weight loss for each of the phase 3 placebo controlled weight loss trials, you can find them in the supplemental materials here
The analysis also found most enrollees using the drugs lived in the southern, central, or northern parts of Mississippi not along the Mississippi Delta on the western side of the state, where obesity rates are highest, at nearly 50%
Notably, the LVFS was calculated by the formula: LVFS= (LVIDdLVIDs)100/LVIDd